Ligand Pharmaceuticals Inc. (LGND) Is At $115.00 Formed Wedge; Invacare (IVC)’s Sentiment Is 1.36

June 8, 2017 - By Michael Collier

Ligand Pharmaceuticals Inc. (LGND) formed wedge up with $118.45 target or 3.00% above today’s $115.00 share price. Ligand Pharmaceuticals Inc. (LGND) has $2.42B valuation. The stock increased 2.56% or $2.87 during the last trading session, reaching $115. About shares traded. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has declined 2.87% since June 8, 2016 and is downtrending. It has underperformed by 19.57% the S&P500.

Invacare Corporation is a manufacturer and distributor for medical equipment used in non-acute care settings. The company has market cap of $445.66 million. The Company’s geographical divisions are Europe; North America, which includes North America/Home Medical Equipment and Institutional Products Group (IPG) divisions, and Asia/Pacific. It currently has negative earnings. The Firm makes and distributes three product categories: mobility and seating, lifestyle and respiratory therapy.

Among 5 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Ligand Pharmaceuticals had 12 analyst reports since September 3, 2015 according to SRatingsIntel. The stock of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has “Buy” rating given on Friday, December 18 by Roth Capital. TH Capital maintained Ligand Pharmaceuticals Inc. (NASDAQ:LGND) rating on Wednesday, September 30. TH Capital has “Buy” rating and $140 target. The firm has “Sell” rating by Deutsche Bank given on Friday, August 5. The stock has “Overweight” rating by Stephens on Wednesday, April 13. TH Capital maintained Ligand Pharmaceuticals Inc. (NASDAQ:LGND) on Thursday, November 19 with “Buy” rating. The stock has “Buy” rating by Roth Capital on Wednesday, September 30. The stock has “Buy” rating by Roth Capital on Friday, March 11. Roth Capital maintained the stock with “Buy” rating in Monday, September 21 report. On Thursday, November 19 the stock rating was maintained by Roth Capital with “Buy”. The stock of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has “Buy” rating given on Friday, December 18 by TH Capital.

Since February 27, 2017, it had 0 insider buys, and 6 sales for $9.73 million activity. Aryeh Jason sold 32,000 shares worth $3.40 million. 4,000 shares valued at $428,240 were sold by HIGGINS JOHN L on Wednesday, March 8. $711,214 worth of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) was sold by FOEHR MATTHEW W.

Investors sentiment increased to 1.2 in 2016 Q4. Its up 0.12, from 1.08 in 2016Q3. It improved, as 23 investors sold Ligand Pharmaceuticals Inc. shares while 85 reduced holdings. 39 funds opened positions while 91 raised stakes. 22.77 million shares or 1.00% less from 23.00 million shares in 2016Q3 were reported. Texas-based Texas Permanent School Fund has invested 0.02% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Bessemer Group Inc reported 0% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). The New York-based Sg Americas Secs Limited Liability Com has invested 0.01% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Mason Street Advsrs Ltd holds 4,156 shares. Clearbridge Ltd Com, Maryland-based fund reported 81,055 shares. Amalgamated Natl Bank, a New York-based fund reported 2,525 shares. Gotham Asset Mgmt Ltd has 0.04% invested in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 33,965 shares. Raymond James has 8,056 shares for 0% of their portfolio. Ameriprise reported 0.02% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Cubist Systematic Strategies Lc has invested 0.03% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Tocqueville Asset Mgmt Ltd Partnership holds 0.03% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 20,216 shares. 114,669 are held by Blair William Co Il. Brown Advisory owns 5,730 shares or 0% of their US portfolio. Matarin Cap Mngmt Limited Co holds 50,922 shares or 0% of its portfolio. 9,775 are owned by Arizona State Retirement System.

Krensavage Asset Management Llc holds 5.16% of its portfolio in Invacare Corporation for 1.10 million shares. Adirondack Research & Management Inc. owns 510,498 shares or 2.26% of their US portfolio. Moreover, Daruma Capital Management Llc has 2.21% invested in the company for 2.97 million shares. The Wisconsin-based Heartland Advisors Inc has invested 1.53% in the stock. Irving Magee Investment Management, a Pennsylvania-based fund reported 298,680 shares.